BPC
APGE icon

Banque Pictet & Cie’s Apogee Therapeutics APGE Stock Holding History

Banque Pictet & Cie’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,960
Closed -$1.68M – 334
2026
Q1 		$1.68M Sell
19,960
-21,840
-52% -$1.59M 0.01% 233
2025
Q4 		$3.16M Buy
+41,800
New +$2.63M 0.02% 177

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Banque Pictet & Cie's APGE Position: Q2 2026 in Review

Banque Pictet & Cie sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 19,960 shares — an estimated $1.68M sold.

Banque Pictet & Cie first reported a position in APGE in Q4 2025 and held it in 2 quarters. The position peaked at $3.16M in Q4 2025. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Banque Pictet & Cie reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Banque Pictet & Cie sold 19,960 Apogee Therapeutics shares in Q2 2026, an estimated $1.68M.
  • Banque Pictet & Cie first reported a position in Apogee Therapeutics in Q4 2025 and held it in 2 quarters.
  • Banque Pictet & Cie's Apogee Therapeutics position peaked at $3.16M in Q4 2025.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Banque Pictet & Cie's 13F filing for Q2 2026, filed 24 Jul 2026.